DiscGenics welcomes you to NASS 2022!
DiscGenics is a privately held, late-stage clinical biopharmaceutical company developing allogeneic, cell-based regenerative therapies for musculoskeletal degeneration. Its lead candidate, IDCT (rebonuputemcel), is a single-injection biologic designed to halt progression and regenerate lumbar discs. Backed by a successful Phase I/II trial, a Phase III clinical program for IDCT is currently underway in the the U.S. IDCT has received both RMAT and Fast Track designations from the FDA.